Drug Search Results
More Filters [+]

BCD-054

Alternative Names: bcd-054, bcd054, bcd 054
Latest Update: 2023-01-01
Latest Update Note: PubMed Publication

Product Description

For Relapsing-remitting Multiple Sclerosis (Sourced from: https://clinicaltrials.gov/ct2/show/NCT02744222)

Mechanisms of Action: Unknown

Novel Mechanism: Yes

Modality: Large Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Biocad
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for BCD-054

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Multiple Sclerosis, Relapsing-Remitting

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

BCD-054-2

P3

Completed

Multiple Sclerosis, Relapsing-Remitting

2018-11-23

81%

BCD-054-1

P1

Completed

Healthy Volunteers

2015-10-01

Recent News Events